In 1995, Bausch + Lomb collaborated for a clinical trial with government researchers at the National Eye Institute. The goal: To see if a high dose nutrient formula can help people with Age-related Macular Degeneration (AMD).
NEI researchers concluded their first
five-year clinical Age Related Eye Disease
Study participants ages 55 to 80 years, with and without AMD.
Reduced risk of moderate vision loss after five years.
Reduction in risk of AMD progression in those with moderate to advanced AMD.
Participants showed continued effects at study follow-up in 2006.
Based on new learnings around AMD, the
NEI researchers sought to improve the
original AREDS formula.
Study participants ages 50 to 85, with AMD.
Clinical centers across the U.S.
Length of AREDS2 study.
Reduced risk of progressing to advanced AMD, compared to patients taking the original AREDS formulation.1
1. No clinically statistically significant differences in AEs between treatment groups. Post-hoc subgroup analysis.
The NEI recommends the AREDS 2 formula for helping to reduce the risk of progression in moderate to advanced AMD.
Talk to your doctor to determine if the AREDS 2 formula is right for you.
* Percent Daily Values (DV) Based on a 2000-calorie diet
**Daily Value not established
The National Eye Institute is working on its report on the AREDS 2 10-year
follow-up study, and we'll be announcing the results soon.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Save up to $4.00
Valid on any Bausch + Lomb PreserVision Eye Vitamin and Mineral Supplement (60 ct or larger).
Your Comprehensive Resource for AMD
Information. Support. Savings.
by Bausch + Lomb
AREDS and AREDS2 are registered trademarks of the United States Department of Health and Human Services (HHS).
All information and materials on this site pertain to the U.S. only, unless otherwise indicated.
© 2020 Bausch & Lomb Incorporated or its affiliates. PVN.0061.USA.20
CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION